Use of Platelet-Rich Plasma in Patients with Melasma

Abstract

Introduction: In the last decade, some studies report the potential effect of platelet-rich plasma in the treatment of melasma.

Objective: To determine the clinical-therapeutic response of patients diagnosed with melasma treated with platelet-rich plasma.

Methods: An experimental, longitudinal and prospective study was conducted in the dermatology service of the Miguel Enríquez Clinical Surgical Teaching Hospital between January 2019 and December 2020.

Results: 52.2% of patients were between 30 and 39 years of age. 86.9% were women. A total of 43.5% were considered phototype III. A total of 73.9% were associated with photoexposure as a risk factor. The distribution pattern was facial center in 69.6%. In 56.5% of cases, the melasma was epidermal and of mild intensity. Response to treatment was excellent in 60.9% of patients and response time was between 4-8 weeks in 21.7%. Erythema was an adverse event of 10.9%.

Conclusions: Response to treatment was considered excellent in most patients and the time to reach it was less than eight weeks in most patients. A low incidence of adverse events was observed, demonstrating that platelet-rich plasma may be a safe and effective treatment option.